bioMérieux S.A. (EPA:BIM)

Market Cap	10.63B -21.5%
Revenue (ttm)	4.07B +2.3%
Net Income	397.50M -8.0%
EPS	3.34 -8.2%
Shares Out	117.95M
PE Ratio	26.99
Forward PE	19.02
Dividend	0.98 (1.07%)
Ex-Dividend Date	Jun 9, 2026

Volume	35,143
Average Volume	131,061
Open	90.15
Previous Close	90.15
Day's Range	90.15 - 91.05
52-Week Range	87.60 - 128.30
Beta	0.67
RSI	42.56
Earnings Date	Jul 28, 2026

About bioMérieux

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1963
• Employees: 15,226
• Stock Exchange: Euronext Paris
• Ticker Symbol: BIM

Financial Performance

In 2025, bioMérieux's revenue was 4.07 billion, an increase of 2.26% compared to the previous year's 3.98 billion. Earnings were 397.50 million, a decrease of -8.03%.